| Demographic | |
| Median age, years (range) | 55 (22–75) |
| Female, no. (%) | 18 (75) |
| Disease status: | |
| Median disease duration, years (range) | 12 (0.9–50) |
| Erosive disease, no. (%) | 24 (100) |
| Nodular disease, no. (%) | 9 (38) |
| Median IgM-RF, kU/litre (IQR) | 75 (46–159) |
| Median ACPA, kU/litre (IQR) | 240 (95–1031) |
| Median DAS28, (IQR) | 6.5 (1.1) |
| Median ESR, mm/h (IQR) | 37 (19–55) |
| Median CRP, mg/dl (IQR) | 24 (10–76) |
| Medications: | |
| Median no. of previous DMARDs, (IQR) | 4 (2–5) |
| Median no. of previous biological agents, (IQR) | 2 (1–3) |
| Median methotrexate dosage, mg/week (IQR) | 15 (10–25) |
| Corticosteroids, no. (%) | 16 (67) |
| Median prednisone dosage, mg/day (IQR) | 5 (0–10) |
ACPA, anti-cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; IQR, interquartile range; RF, rheumatoid factor.